U.S. flag

An official website of the United States government

Medicaid Drug Programs (MDP) System Access

CMS fully implemented a new Medicaid Drug Programs (MDP) system on November 15, 2021, which replaced the Drug Data Reporting for Medicaid (DDR) system.  As of November 2, 2021, DDR is no longer accessible to users.  All existing state and labeler DDR users prior to November 15, 2021 were transitioned to the MDP system.

Drug manufacturers who need to report or certify their data must apply for access to the Medicaid Drug Programs (MDP) system. Note: Access to specific data will be designated by each drug manufacturer's Technical Contact (TC), MDRP Contact or State DUR Contact as applicable.

Drug manufacturers who would like to request a new National Drug Rebate Agreement (NDRA) or a reinstatement into the program should follow the instructions found on the Medicaid National Drug Rebate Agreement (NDRA) page.

States who require access to the Drug Utilization Review (DUR) Surveys, report State Drug Utilization Data (SDUD), or States wishing to view select Medicaid Drug Rebate data must obtain access to the Medicaid Drug Programs (MDP) system.

For detailed instructions and screenshots for all MDP-related CMS Identity Management system (IDM) tasks, including requesting access, please refer to the IDM Instruction Guide for MDP Users (PDF, 246.14 KB)

If you have MDP access questions, please email the MDP Access Team at MDP@cms.hhs.gov. For Portal and IDM role request issues, please contact the MDP IDM Help Desk at mdp-ddrhelpdesk@softrams.com or 1-(833) 637-6370.

Questions on the Medicaid Drug Rebate Program?  Email MDROperations@cms.hhs.gov.

Disclaimer: Please note that the information provided on this web page does not bind or obligate the Centers for Medicare and Medicaid Services (CMS).  The statements included on this web page are intended to provide information on the Drug Data Reporting and Medicaid Drug Program Systems and do not in any way revise or modify the requirements set forth in Section 1927 of the Act, the national drug rebate agreement (NDRA), subsequent program releases, or regulations.

Page last updated on November 8, 2021